Search

Your search keyword '"Hoschler, Katja"' showing total 350 results

Search Constraints

Start Over You searched for: Author "Hoschler, Katja" Remove constraint Author: "Hoschler, Katja"
350 results on '"Hoschler, Katja"'

Search Results

2. Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

3. Genomic investigations of unexplained acute hepatitis in children

4. Paediatric acute hepatitis of unknown aetiology: a national investigation and adenoviraemia case-control study in the UK

6. Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study

7. Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England

10. Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK

11. Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom

12. End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain

13. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

16. Optimizing mood prior to influenza vaccination in older adults: A three-arm randomized controlled trial.

18. High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023

21. Post-pandemic development of sentinel surveillance of respiratory disease, in the context of the WHO mosaic framework: protocol for the English primary care network 2023-2024 (Preprint)

22. Postpandemic Sentinel Surveillance of Respiratory Diseases in the Context of the World Health Organization Mosaic Framework: Protocol for a Development and Evaluation Study Involving the English Primary Care Network 2023-2024 (Preprint)

24. Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

25. ADCC:An underappreciated correlate of cross-protection against influenza?

26. A case of swine influenza A(H1N2)v in England, November 2023.

28. Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study

31. An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study

37. H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study

38. Genomic Investigations of Acute Hepatitis of Unknown Aetiology in Children

39. Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study

41. Fast Rise of Broadly Cross-Reactive Antibodies after Boosting Long-Lived Human Memory B Cells Primed by an MF59 Adjuvanted Prepandemic Vaccine

42. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines

46. Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies following Stem Cell Transplantation

48. SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements

49. Antibody Persistence after Primary Sars-Cov-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study

50. Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2

Catalog

Books, media, physical & digital resources